What does the Wegovy pill cost, with and without insurance?

NovoCare: "Self-pay pricing varies by dose. Patients pay $149 for each month of 1.5 mg, $199 per month for 4 mg and $299 per month for 9 mg and 25 mg. Eligibility and restrictions apply. One month defined as 1 bottle of 30 tablets." "By opting to pay outside of your insurance, any money spent will not count toward your out-of-pocket limits or deductible." The same page states: "Wegovy® pill has a list price of $1,349.02/package" and "Wegovy® pen has a list price of $1,349.02/package". For the pen: "Patients new to the Wegovy® Savings offer or NovoCare® Pharmacy pay $199 for each month of 0.25 mg & 0.5 mg. Offer for 2 monthly fills through December 31, 2026, then $349 per month for Wegovy® 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, or 2.4 mg and $399 per month for Wegovy® HD 7.2 mg." "One month defined as 1 box of 4 pens of Wegovy®."

Novo Nordisk, NovoCare: Wegovy · source

NovoCare Pharmacy's terms list the Wegovy tablets standard price for one, two and three months: 1.5 mg $149.00, $298.00, $447.00; 4 mg $199.00, $398.00, $597.00; 9 mg and 25 mg $299.00, $598.00, $897.00. A limited-time $149.00 price for 4 mg applied only if "the prescription is written on or before 8/31/26, received by the pharmacy by the end of day on 8/31/26, and shipped on or before 9/30/26." A one-month fill is "1 bottle of 30 tablets equivalent to a 30-day supply", and NovoCare "operates through licensed pharmacies that dispense product under a cash/self-pay model, and insurance is not accepted."

Novo Nordisk, NovoCare Pharmacy terms and pricing · source

Wegovy savings offer terms: "For patients with commercial insurance who have coverage for Wegovy® (semaglutide) tablets 1.5 mg, 4 mg, 9 mg, 25 mg: Pay as little as ("PALA") $25, subject to a maximum savings of $100 per 1-month prescription … $200 per 2-month prescription, or $300 per 3-month prescription." "Patient is not eligible if he/she is enrolled in any federal or state health care program with prescription drug coverage, such as Medicaid, Medicare, VA, DOD, TRICARE". "Savings Offer benefits are set at the discretion of Novo Nordisk and may change without notice."

Novo Nordisk, NovoCare: Wegovy Savings Offer terms · source

NovoCare's savings offer page: "Individuals with both commercial and government-funded plans ARE considered patients with government insurance." "The Federal Employees Health Benefits (FEHB) Program, Affordable Care (Health Exchange) Plans, and insurance provided through state employee plans are NOT federal or state government health care programs for purposes of this savings offer." "Patients who use this savings offer and are enrolled in government, state, or federally-funded medical or prescription benefit programs are able to pay the self-pay price for their prescription."

Novo Nordisk, NovoCare: Wegovy savings offer · source

TrumpRx lists the Wegovy pill at strengths 1.5, 4, 9 and 25 mg, 30 tablets, with an "Original Price $1,349.02", and states: "This is an out-of-pocket price. If you have insurance, check your co-pay first—it may be even lower." It adds that "Self-pay pricing varies by dose" and "Government beneficiaries excluded"; "Present the coupon at your pharmacy to claim your TrumpRx savings."

TrumpRx.gov, Wegovy pill · source

CMS: "an eligible GLP-1 drug is any of the following products when used to reduce excess body weight and maintain weight reduction: Foundayo®, Wegovy® (injection and tablets), and Zepbound® (KwikPen®)." The page notes: "This was updated on April 6, 2026, to include Foundayo® following FDA approval."

Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge: information for Part D plans, effective August 2026 · source

CMS: the Bridge gives access "between July 1, 2026, and December 31, 2027." "Eligible beneficiaries will have a $50 copay … the Part D deductible will not apply, no part of the $50 copay counts towards the beneficiary's TrOOP costs, and there is no low-income subsidy (LIS) provided for LIS beneficiaries."

Centers for Medicare & Medicaid Services, Medicare GLP-1 Bridge, effective July 2026 · source

Novo Nordisk's Wegovy site: "The Medicare GLP-1 Bridge is a temporary federal program that gives eligible Medicare Part D beneficiaries access to all dose strengths of both Wegovy® pen and pill for just $50 per month between July 1, 2026, and December 31, 2027."

Novo Nordisk, Wegovy: save on Wegovy · source

Wegovy's prescribing information lists "Tablets: 1.5 mg, 4 mg, 9 mg and 25 mg", each a "Bottle of 30 tablets", and states "The recommended maintenance dosage of WEGOVY® tablets is 25 mg orally once daily". The tablets are indicated to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight, and to reduce excess body weight and maintain weight reduction long term.

Novo Nordisk, Wegovy prescribing information (revised June 2026), effective June 2026 · source

Novo Nordisk, December 22, 2025: "the US Food and Drug Administration (FDA) has approved once-daily Wegovy® pill, the first oral GLP-1 medicine for obesity in the US."

Novo Nordisk, news release, effective December 2025 · source

Novo Nordisk, February 24, 2026: "effective January 1, 2027, the company will lower the list price, or wholesale acquisition cost (WAC), of Wegovy® (semaglutide) injection 2.4 mg and tablets 25 mg, Ozempic® … and Rybelsus® … to $675". "These changes in list price do not have an impact on direct-to-patient, self-pay prices".

Novo Nordisk, news release, effective February 2026 · source

First approvals are short and renewal is measured. The program issues five months for "Wegovy injection or tablet, Wegovy HD", six for "Foundayo, Xenical or Zepbound", four for Contrave, Qsymia or Saxenda, and three for the older stimulant appetite suppressants. To reauthorize, most drugs need "Weight loss of ≥ 5% of baseline body weight" — 3 percent for Qsymia, 4 percent for Saxenda — plus continued lifestyle modification, and the renewal then runs twelve months.

UnitedHealthcare, Clinical Pharmacy Programs, "Prior Authorization/Notification – Plans with Weight Loss/Appetite Suppression Medication Coverage" (2026 P 1114-22), effective September 2026 · source

Bridge eligibility is attested by your prescriber and needs a BMI of 35 or more; or 30 or more with heart failure with preserved ejection fraction, uncontrolled hypertension, or chronic kidney disease stage 3a or worse; or 27 or more with pre-diabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

Centers for Medicare & Medicaid Services, effective August 2026 · source